The use of a monoclonal antibody against a proliferating cell nuclear matrix antigen in the study of solid human tumors

Yankulov, Krassimir; Hadjiolova, Krassimira V.; Kounev, K. V.; Getov, Chr.; Hadjiolov, A.A.

doi:10.1002/ijc.2910430510

Cited by 10 publications

(1 citation statement)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two-dimensional gel electrophoresis and immunoblotting studies indicate that the antigen increases in mitotic cells compared with interphase cells and this is consistent with immunofluorescence studies indicating maximal fluorescence during metaphase and anaphase (Todorov et al 1988). p125/6.5 antigen is present in a variable proportion of cells in a range of tumours and it is seen in a fraction of cells in normal tissues which approximates to those cells known to be cycling, as determined by more conventional methods such as tritiated thymidine incorporation (Yankulov et al, 1989). Although a detailed assessment of normal tissue has not yet been reported, a recent immunocytochemical study of spermatogenesis (Hadjiolova et al, 1989) provides convincing evidence for the proposition that the pl25/6.5 nuclear matrix antigen is characteristic both of proliferating cells and of those cells committed to proliferation.…”

Section: P125/6*5supporting

confidence: 78%

Immunohistochemical markers of cellular proliferation: achievements, problems and prospects

1990

View full text Add to dashboard Cite

Section: P125/6*5supporting

confidence: 78%

Immunohistochemical markers of cellular proliferation: achievements, problems and prospects

1990

View full text Add to dashboard Cite

Alterations of growth fraction and DNA content in K562 cells by differentiating agents

et al. 1990

View full text Add to dashboard Cite

The growth fraction, estimated by the monoclonal antibody Ki-67 labeling, and DNA content, assessed by ethidium bromide staining, were determined simultaneously in K562 leukemic cells by flow cytometry. A multiparametric analysis enabled the fraction of the cell population with GI, S, and G, + M contents in Ki-67-positive and Ki-67-negative cells to be evaluated.Butyric acid (BUT) was used as positive control. The fraction of Ki-positive cells decreased with the BUT concentration, while the proportion of cells with G, DNA content increased only in the Ki-negative cells.Adriamycin, aclacinomycin A, and fagaronine induced differentiation, as assessed by benzidine staining and glycophorin A expression. These drugs decreased the fraction of Ki-positive cells by more than 50% for both anthracyclines and by 25% for fagaronine. Following treatment, Ki-negative cells displayed a G,, but also a G, and a S DNA content in different proportions, indicating that induction of quiescent cells by differentiating agents is not a uniform process and is worthy of interest.Key terms: FCM, proliferation-associated antibody Ki-67, glycophorin A, erythroid differentiationIn cancer therapy, it is of interest to evaluate the tumour growth fraction (GF). It reflects the rate of tumour growth which is a factor of prognosis (8,16,29) and the fraction of cells sensitive to anticancer agents. Non-cycling cells have been described with a GI but also with a G2 and even an S DNA content, both in vitro (4,13,15) and in vivo (11); "recruitment" and "synchronizing" protocols will be better scheduled if the DNA content distributions of the proliferating and quiescent cells are known. A recent strategy in cancer chemotherapy has been to induce cell maturation and inhibit cell growth (21,23) without cell killing. In this case, it will be interesting to know precisely the cell cycle parameters, i.e., the GF and the DNA distributions of both cycling and non-cycling cells. Classical methods to determine GF by using radioactive DNA precursors (11,311, the bromodeoxyuridine (BrdU) antibody technique (3,27), or dye staining of both DNA and RNA (2,4,13) are difficult and time consuming. Recently, methods using monoclonal antibodies (MoAb) have been described. They are directed against human alpha DNA polymerase (11, a heterochromatin-associated antigen (MoAb 244-7) ( 5 ) , a proliferating cell nuclear matrix antigen (32), a nuclear antigen (M 150,000) (9), nuclear antigen p105 (161, the transferrin receptor (25), the ribonucleotide reductase M1 subunit (20), and especially a nuclear-matrix-associated proliferation-related antigen (MoAb Ki-67) (18,30). Different attempts were carried out to stain simultaneously cells with Ki-67 MoAb and propidium iodide (3,12,24). We used simultaneously Ki-67 and ethidium bromide (EB) and then separately measured the DNA content of cells according to their reactivity with Ki-67 MoAb.

show abstract

Expression of proliferating cell nuclear antigen, Ki‐67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: An immunochemical study with clinical, pathobiological, and histologic correlations

Pelosi¹,

Bresaola²,

Rodella³

et al. 1994

Diagnostic Cytopathology

View full text Add to dashboard Cite

Sixty-six unselected breast cancers were analyzed in cytologic smears and histologic sections for the expression of Ki-67, proliferating cell nuclear antigen (PCNA), estrogen receptor protein (ERP), and p53 protein using a standard immunochemical method. The results, expressed as both positive cases and labelling index (LI), were compared with clinical and pathobiological variables. Ki-67 and PCNA immunostaining was seen in all cases, whereas ERP was detectable in 46/63 cases and p53 protein in 20/66 cases. The expression of these markers was generally lower in cytology than in histology, though the differences were not statistically significant. PCNA-LI and Ki-67-LI were closely correlated (P < 0.001), the mean PCNA:Ki-67 ratio being 0.92 +/- 0.57. Occasional discrepancies, however, were found. PCNA and Ki-67 expression was associated with an increase in histologic grade and a decrease in ERP content of tumors, whereas p53 was statistically associated with no clinical or pathobiological variables. The data suggest that proliferative activity and oncogene overexpression may be reliably evaluated in breast cancer by FNA cytology, though PCNA is not a suitable indicator for cell proliferation. The results do not resolve the issue as to whether immunostaining for p53 protein constitutes a dedifferentiation product of the tumor, or is a fundamental aspect of the malignant progression. Survival studies in a larger series of tumors are thus needed to elucidate this point.

show abstract

The use of a monoclonal antibody against a proliferating cell nuclear matrix antigen in the study of solid human tumors

Cited by 10 publications

References 16 publications

Immunohistochemical markers of cellular proliferation: achievements, problems and prospects

Immunohistochemical markers of cellular proliferation: achievements, problems and prospects

Alterations of growth fraction and DNA content in K562 cells by differentiating agents

Expression of proliferating cell nuclear antigen, Ki‐67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: An immunochemical study with clinical, pathobiological, and histologic correlations

Contact Info

Product

Resources

About